Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pratley

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Cardiovascular Diabetology|September 28, 2024
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trialStefano Del Prato, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Molecular & Cellular Proteomics : MCP|November 4, 2022
A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer-Associated Stellate Cell Small Extracellular VesiclesBhaswati Sarcar, Bin Fang, Victoria Izumi, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
Circulation|August 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Lauren Heath, et al.
Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
Circulation|February 21, 2023
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O TrialHertzel C Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Journal of Diabetes and Its Complications|June 26, 2022
The effect of vitamin D supplementation on cardiovascular risk in patients with prediabetes: A secondary analysis of the D2d studyCyrus Desouza, Ranee Chatterjee, Ellen M Vickery, et al.
The New England Journal of Medicine|July 2, 2021
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesHertzel C Gerstein, Naveed Sattar, Julio Rosenstock, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Cardiovascular Diabetology|September 28, 2024
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trialStefano Del Prato, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Molecular & Cellular Proteomics : MCP|November 4, 2022
A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer-Associated Stellate Cell Small Extracellular VesiclesBhaswati Sarcar, Bin Fang, Victoria Izumi, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
Circulation|August 30, 2024
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Lauren Heath, et al.
Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
Circulation|February 21, 2023
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O TrialHertzel C Gerstein, Zhuoru Li, Chinthanie Ramasundarahettige, et al.
Journal of Diabetes and Its Complications|June 26, 2022
The effect of vitamin D supplementation on cardiovascular risk in patients with prediabetes: A secondary analysis of the D2d studyCyrus Desouza, Ranee Chatterjee, Ellen M Vickery, et al.
The New England Journal of Medicine|July 2, 2021
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesHertzel C Gerstein, Naveed Sattar, Julio Rosenstock, et al.
Pageof 7